
|Articles|July 1, 2001
- Pharmaceutical Executive-07-01-2001
- Volume 0
- Issue 0
Generic Threat
Author(s)Kevin Gopal
Epsom, Surrey, United Kingdom—Pharmaceutical companies struggle to be taken seriously when they talk of facing pressures. A quick look at the bottom line often suggests they are overstating their worries. But new evidence shows they are being squeezed by generic competition and falling R&D output.
Advertisement
Articles in this issue
over 24 years ago
Pharmacies: OTC Price Warsover 24 years ago
One Disease at a Timeover 24 years ago
Overview of the Industry: A World of Opportunitiesover 24 years ago
The Power Shiftover 24 years ago
A Giant Stumblesover 24 years ago
Overruled: No More Dual Pricingover 24 years ago
SubmergedNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
What Governance Resets Should Pharma Companies Take in Response to AI?
3
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5




